Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135453 · ClinicalTrials.gov registry record · Phase 4
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
NCT07135453 is a Phase 4 study that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants.
The verdict
NCT07135453, a Phase 4 study, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
Study Summary
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
Interventions
- BIOLOGICAL Pneumococcal Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07135453
The ClinicalTrials.gov registry entry for NCT07135453 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pneumococcal Vaccine is the first listed.
NCT07135453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07135453 about?
NCT07135453 is a clinical study titled "Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines". The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each v...
What is the current status of trial NCT07135453?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07135453?
The interventions under investigation include: Pneumococcal Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT07135453?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.